The SneakPeek® Early Gender Test was previously shown to be 99.9% accurate in determining fetal sex as early as seven weeks of gestation. To our knowledge, no prior study has shown fetal sex identification from maternal plasma earlier than seven weeks of gestation with high accuracy. The SneakPeek assay was further optimized to enable fetal sex identification at earlier gestations and its performance characteristics were determined at 6-weeks’ gestation.
Multiple studies have demonstrated SneakPeek® Early Gender Test’s ability to accurately determine fetal sex as early as 8 weeks gestation with greater than 99% accuracy. The qPCR-based assay was further optimized to determine fetal sex at 7 weeks gestation. The objective of this study was to evaluate SneakPeek’s clinical performance for noninvasive prenatal testing (NIPT) to determine fetal sex as early as 7 weeks gestation.
The advancement of prenatal DNA technology and growing demand for early fetal sex determination have created a need for a simple and easy-to-use blood collection device that eliminates the pain and difficulty individuals encounter when utilizing traditional methods of blood collection such as venipuncture or lancet fingerstick. In this study, Gateway Genomics, the leading provider of fetal sex testing, introduces “SneakPeek Snap”, a novel microneedle-based, self-administered blood collection device that simplifies at-home blood collection for fetal sex testing.
Early fetal sex determination has become more prevalent among parents interested in planning for their unborn child. Current advances in non-invasive prenatal testing (NIPT) have facilitated this desire with safe and efficient methods such as the SneakPeek® Early Gender DNA Test (“SneakPeek”).
There are many momentous events that accompany the journey of childbirth, one of which is the discovery of the fetus’s sex. What most expecting families are unaware of is that in addition to the traditional approaches, there exists newer developed technologies that allow for an earlier determination of the fetus’s sex.
In order to assess the perceived benefits of early fetal sex determination, Gateway Genomics constructed a study in which postpartum women provided insight into the effect of the early gender test on their pregnancy journey. Results from the survey confirm that early fetal sex determination does confer various benefits to the childbearing process.
Prior studies have shown that SneakPeek® Early Gender Test can accurately determine fetal sex as early as 9 weeks gestation using a qPCR-based assay. The purpose of this study was to evaluate the clinical performance of SneakPeek® for noninvasive prenatal testing (NIPT) to determine fetal sex at an earlier time point: 8 weeks gestation.
SneakPeek® Early Gender Test (Gateway Genomics) is a qPCR-based assay that utilizes a microvolume of maternal plasma to determine the fetal sex as early as 9 weeks gestation. In this study, we aimed to evaluate the accuracy of SneakPeek Early Gender Test for fetal sex determination in self-collected maternal blood samples.
A qPCR-based assay, SneakPeek® Early Gender Test (Gateway Genomics), has been developed to determine fetal sex as early as 9 weeks gestation using a micro-volume of maternal plasma. The purpose of this study was to assess the clinical performance of SneakPeek for noninvasive prenatal testing (NIPT) of fetal sex.
You'll go through Sezzle's 1-minute sign up process without having to leave checkout. Simply select Sezzle as your payment method when checking out.